Message Font: Serif | Sans-Serif
 
No. of Recommendations: 3
Still like it, though have accepted that it's likely to languish until 3/4Q 2020.

With that said, they have multiple drivers for growth...

-they are starting zynteglo in Germany likely in Q2.
-BLA for US usage in 2H20
-enrolling in second P3 for pediatric sickle cell
-Submission of a BLA for relapsed and refractory multiple myeloma 1H20
-Submission of a BLA to FDA as well as European Medicines Agency for Lenti-D in patients with cerebral adrenoleukodystrophy by the end of 2020.

They are moving forward, it's a bit slower than expecting by maybe a quarter. These are not setbacks by years. The ide-cel drug may take a hit as it's a hot market and other drugs may prove more beneficial (not sure on that yet)- but the gene therapy space will be a large money printing moat, and BLUE has a big lead and lots of safety data. And a small market cap for so many billion+ shots on goal (I count at least 2, likely 3, with ide-cel a wildcard).

Looking at their clinical segment of the release, it looks like the second half of 2020 will be ripe with data:



Submission for presentation of ide-cel clinical data from the KarMMa study in the first half of 2020, in partnership with Bristol-Myers Squibb.
Submission for presentation of ide-cel clinical data from the CRB-401 study in 2020, in partnership with Bristol-Myers Squibb.
Initiation of the Phase 3 HGB-210 study of LentiGlobin for SCD in patients with a history of vaso-occlusive crises in the first half of 2020.
Initiation of the Phase 3 HGB-211 study of LentiGlobin for SCD in patients at risk of stroke in 2020.
Updated data presentation from ALD-102 in patients with CALD by the end of 2020.
Updated data presentation from the Northstar-2 (HGB-207) clinical study in patients with transfusion-dependent ß-thalassemia (TDT) and non-ß0/ß0 genotypes by the end of 2020.
Updated data presentation from the Northstar-3 (HGB-212) clinical study in patients with TDT and a ß0/ß0 genotype or an IVS-I-110 mutation by the end of 2020.
Updated data presentation from HGB-206 clinical study in patients with SCD by the end of 2020.


In closing, I still like it, but am being patient. Nothing has really changed the thesis.
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.